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Multistage carcinogenesis consists of initiation,
promotion, and progression. Tumor promo-
tion is a stepwise process: It occurs with com-
paratively low frequency, requires the chronic
action of tumor promoters, and does not neces-
sarily involve genotoxic damage. The mouse
skin model is an excellent example of multi-
stage carcinogenesis. The concentration of ini-
tiator (typically dimethylbenz[a]anthracene;
DMBA) can be decreased to produce genotoxic
damage in the absence of tumor formation.
Sequential exposure of initiated cells to various
tumor promoters (e.g., 12-O-tetradecanoyl-
phorbol-13-acetate; TPA) at an optimal con-
centration results in a robust tumor response.
Because tumor initiation occurs rapidly and
tumor promotion requires several months (i.e.,
20–40% of a mouse lifetime), tumor promo-
tion is considered a rate-limiting step (1). In
vivo studies support a dose threshold for skin
papilloma formation in response to TPA (2,3).
Therefore, defining molecular thresholds in
transformation-related signal transduction
pathways is expected to provide a scientific
basis to improve cancer risk assessment. 
Although in vivo data are significant to
whole organisms, in vitro systems are more
readily manipulated and have advantages in
terms of cost and time. The JB6 mouse
epidermal cell model of genetic variants is
unique in that it allows a detailed investiga-
tion of the molecular events speciﬁc to tumor
promotion. Promotion-sensitive clones of the
mouse epidermal cell line JB6 (clone 41)
respond irreversibly to tumor promoter treat-
ment with colony growth under anchorage-
independent conditions and induced tumor
formation (1,4). Anchorage-independent
transformation has been observed in clone 41
cells treated with TPA, epidermal growth fac-
tor (EGF), tumor necrosis factor alpha
(TNFα) (5), and other tumor promoters (6).
Molecular events implicated as required for
tumor promotion or tumor maintenance in
the JB6 model have proved to be predictive
for initiation-promotion mouse skin carcino-
genesis in vivo (7) and for human ker-
atinocyte progression (8,9). Therefore, the
JB6 model provides a common framework to
directly compare transformation-related sig-
nal transduction induced by diverse tumor
promoters acting through different modes of
action. 
In particular, the mitogen-activated protein
kinases ERK-1 and ERK-2 (extracellular signal-
regulated protein kinases 1 and 2) are acutely
activated by many extracellular stimuli and by
oncogene products (10). Overexpression of
ERK-2 converts transformation-resistant cells
to a transformation-sensitive phenotype (11),
and inhibition of ERK activity converts sensi-
tive cells to a transformation-resistant pheno-
type (12). The ERK-deficient JB6 cells are
characterized as deﬁcient in inducible activa-
tor protein-1 (AP-1) transcriptional activity, a
response that is rescued by ERK-2 expression
(7,13–15). Because oncogenic activation of
several signal transduction pathways can
increase AP-1 activity (16,17), these ﬁndings
indicate that activation of ERK-1 and ERK-2
is essential for activation of AP-1 and for
transformation by TPA or EGF in the JB6
model. 
In addition, the serum-response element
(SRE) mediates activation of c-fos transcrip-
tion by growth factors, cytokines, and other
extracellular stimuli that activate mitogen-
activated protein kinase (MAPK) pathways.
SRE is recognized by a dimer of the serum
response factor (SRF), whose binding recruits
the monomeric ternary complex factors (Elk-
1, Sap-1a, and Sap-2) that cannot bind SRE
alone. Whereas Sap-1a is activated only by
ERK and p38 phosphorylation, Elk-1 is acti-
vated by ERKs, JNK/Sapk, and p38 MAP
kinase (18–21). Thus, ERK-dependent phos-
phorylation of Elk-1 and Sap-1a regulate
gene transcription through the SRE, and SRE
activation is therefore a reliable, alternative
indicator of ERK activation. 
Nuclear factor kappa B (NFκB) has been
implicated in gene regulation related to cell
proliferation, apoptosis, adhesion, immune,
and inﬂammatory responses (22). NFκB, like
AP-1 (13), is required for tumor promoter-
induced transformation of JB6 cells (14,15). 
The available data with JB6 cells support
the existence of thresholds in pathways
required for the transformation response,
consistent with putative thresholds for
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The promotion-sensitive mouse epidermal JB6 cells (clone 41) have been used to identify the
tumor-promoting activity of various compounds. Because treatment by tumor promoters [12-O-
tetradecanoylphorbol-13-acetate (TPA), epidermal growth factor (EGF), or tumor necrosis factor
alpha (TNFα)] transforms clone 41 cells to anchorage-independent and tumorigenic phenotypes,
they are considered to be undergoing late-stage tumor promotion. Here we address the question of
how much activation of transformation-relevant transcription factors [activator protein-1 (AP-1),
ternary complex factors (TCFs), or nuclear factor κB (NFκB)] is required for transformation
response and how much tumor promoter produces signiﬁcant risk of transformation. Stable trans-
fectants harboring a reporter construct with an AP-1 response element, serum-response element
(SRE), or NFκB response element were established. We examined the relationship between con-
centration of tumor promoters, key signaling events, and activation of the transcription factors. A
concentration of > 0.2 nM TPA or 0.12 ng/mL (0.02 nM) EGF produced a signiﬁcant increase in
transformation response as well as in extracellular signal-regulated protein kinase (ERK), SRE, or
AP-1 activation. Treatment with > 0.4 U/mL (2.35 pM) TNFα increased NFκB activity and
transformation response in a dose-dependent manner. However, transformation response
decreased at > 33 U/mL TNFα due to a cytotoxic response. These ﬁndings suggest that the signal-
ing pathway leading to the activation of ERK, TCF, and AP-1 proteins constitutes a major factor
determining the risk of tumor promotion by TPA or EGF. Cell toxicity in addition to NFκB acti-
vation should be considered in predicting TNFα-induced transformation response. Key words:
activator protein-1, epidermal growth factor, nuclear factor κB, serum–response element, 12-O-
tetradecanoylphorbol-13-acetate, transformation, tumor necrosis factor-α. Environ Health
Perspect 110:865–870 (2002). [Online 18 July 2002]
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determine if there is an activation threshold
for promoter-induced transformation and to
determine how much activation of transfor-
mation-relevant transcription factors is
required, we established stable reporter
clones. Dose–response relationships of trans-
formation, AP-1, SRE, and NFκB activation
by TPA, EGF, or TNFα revealed activation
levels above which there was risk of neoplastic
transformation.
Materials and Methods
Cell culture and reagents. Promotion-sensi-
tive mouse epidermal JB6 cells, clone 41,
were as previously described and were main-
tained accordingly (23,24). In brief, JB6 
cells were cultured in Eagle’s minimal 
essential medium (EMEM; BioWhittaker,
Walkersville, MD) supplemented with 
4% fetal bovine serum (FBS), 2 mM L-gluta-
mine and 25 mg/mL gentamicin (Life
Technologies/Gibco, Gaithersburg, MD).
TPA was purchased from LKT Laboratories,
Inc. (St. Paul, MN). EGF (receptor grade)
was purchased from Upstate Biotechnology
(Lake Placid, NY, lot 19319). All other cell
culture reagents were purchased from
BioWhittaker or Life Technologies/Gibco.
TNFα was purchased from PeproTech Inc.
(Rocky Hill, NJ). Specific activity is ≥ 1 ×
107 U/mg.
Plasmids and stable transfection. SRE-
luciferase reporter construct containing five
tandem SRE sequences (AGGATGTC-
CATATTAGGACATCT) was purchased
from Stratagene (La Jolla, CA). AP-1 or
NFκB luciferase reporter plasmids consisting
of luciferase reporter gene driven by the pro-
moter harboring the appropriate element
were described previously (13,14). The AP-1
reporter plasmids consist of firefly luciferase
genes driven by an AP-1-responsive promoter
containing four copies of ﬂanked AP-1 con-
sensus sequence (TCGACTATGATGAGT-
CATGGGGC) from GCN4 and a minimal
albumin promoter region with TATA box:
AAGCTTAGAATCTAGTATATTA-
GAGCGAGTCTTTCTGCACACAGAT-
CACCTTTCCTATCAACCCCACTACCA
TACCCTTCCTCCATCTATACCACCC-
TACTCTGCAGGTCGAC.
The NFκB reporter plasmids consisted of
firefly luciferase reporter genes driven by a
minimal NFκB-responsive region from an
interleukin-6 (IL-6) promoter containing two
copies of NFκB-responsive elements in a
sense orientation: GACTCTAGAGGAT-
CAAATGTGGGATTTTCCCAT-
GTGGGATTTTCACATGATCATGGGA
AAATCCCACATGAAAATCCAATTTC-
CGGCC.
Because there are no other known respon-
sive cis-elements identified in the above
sequences, any cross-family activation should
occur at the level of protein–protein, not at
the level of protein–DNA interaction.
We performed transfections according to
the Fugene6 protocol from Roche molecular
biologicals (Indianapolis, IN). In brief, 1 ×
105 cells were seeded in 10-cm dishes. The
next day, 15 µL of Fugene6, 4 µg of reporter
DNA, and 1-0.5 µg of pcDNA empty vector
were added to 0.5 mL of complete medium.
After 10 min of incubation, transfection mix-
ture was added to cell culture dishes. Cells
were incubated for 48 hr. G418 selection was
started on the transfected population with
500 µg/mL. 
Luciferase assay of reporters. We seeded
1 × 104 cells/well of reporter cells in 24-well
plates. On the next day the cells were starved
in EMEM with 0.2% FBS for more than 24
hr to lower the basal transcription factor acti-
vation. We treated the resulting cells with
various concentrations of TPA, EGF, or
TNFα in EMEM with 0.2% FBS for 3 hr.
We observed little or no cell detachment. The
stimulated cells were collected and lysed at 3
hr of treatment. The cells were lysed directly
on the plate after a single wash with phos-
phate-buffered saline. We assayed the result-
ing cell lysates for luciferase activity using the
Luciferase Assay Kit (Promega, Madison, WI)
and DYNEX Luminometer (DYNEX
Technologies, Chantilly, VA). Three inde-
pendent wells were used for each condition in
each experiment. We calculated percent acti-
vation of each reporter by the following equa-
tion: % activation = [sample relative luciferase
units (RLU) – basal RLU]/(maximum RLU –
basal RLU) × 100. We used the average RLU
of three wells as sample RLU.
Western blots. We seeded 1 × 105 cells/well
of cells in six-well plates. Cells were starved as
described under luciferase assay. Cells were
treated with TPA or EGF for 30 min, washed
with ice-cold phosphate-buffered saline once,
then lysed with lysis buffer (2% SDS, 50 mM
Tris-HCl pH 7.5). Western immunoblotting
was performed according to the ECL protocol
from Amersham Pharmacia Biotech, Inc.
(Piscataway, NJ). Anti-ERK-1/2 (p44/42
MAP Kinase) and anti-phosphoERK-1/2 anti-
bodies were purchased from Cell Signaling
Technology, Inc. (Beverly, MA). In brief,
20–40 µg of whole-cell lysates were boiled and
denatured in sample buffer containing SDS
and dithiothreitol (NOVEX, San Diego, CA)
followed by gel electrophoresis using NuPAGE
10% Bis-Tris prepacked gel (NOVEX) in 4-
morpholine-propanesulfonic acid buffer. The
proteins were electro-transferred to nitrocellu-
lose membrane (Schleicher & Schuell, Keene,
NH) using a semidry transfer blotting system
from Enprotech Co. (Hyde Park, MA). The
resulting protein-bound membrane was blot-
ted with selected antibodies and visualized
using ECL reagents (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ) and X-OMAT
AR film (Kodak, Rochester, NY). The band
intensities were monitored by Kodak digital
camera (DC120) and analyzed by its image-
analyzing program (Kodak 1D). We deter-
mined the lowest and highest intensity as 0%
and 100% activation, respectively. Although
the peak activation was observed at 30 min,
ERK activation was sustained for at least 6 hr
(data not shown).
Anchorage-independent transformation
assay. We performed promotions of neoplastic
transformation assays as described previously
(25). In a 60-mm tissue culture dish, 10,000
JB6 cells were resuspended in 1.5 mL of
0.33% agar in EMEM with 10% FBS and
layered over 7 mL of 0.5% agar in EMEM
with 10% FBS. Both layers of agar were sup-
plemented with DMSO, phosphate-buffered
saline, or various concentrations of tumor pro-
moter TPA, EGF, or TNFα. The cells were
cultured at 36°C for 14 days, and the resulting
colonies were counted by an automated image
analysis system supported by Image Pro-Plus
(version 3.0.1) software (Media Cybernetics,
Silver Spring, MD). We scored colonies > 8
cells. The transformation responses are pre-
sented as number of colonies per 10,000 cells
per 60-mm tissue culture dish.
Results
To assess activation response to small-mole-
cule inducers (tumor promoters), we gener-
ated stably transfected reporter cell lines.
Such stable reporter cell lines offer the advan-
tage of eliminating the variability that arises
with repeated transient transfections. Nine,
six, and three clonal transfectants harboring
AP-1-, SRE-, and NFκB-luciferase reporter
constructs were isolated, respectively. All of
them were sensitive to tumor promoter-
induced transformation and exhibited basal
and tumor promoter-induced luciferase activ-
ity. Among them, we selected two clones of
each harboring a luciferase reporter for fur-
ther analysis. 
Activation of MAP kinase ERK-1, -2, and
SRE-dependent transcription by TPA or EGF.
Using anti-phospho-ERK-1/2 antibody, we
measured the amount of phospho-ERK-1/2,
an activated form of ERK, in SRE-luciferase
reporter (S13) cells treated with varying con-
centrations of TPA or EGF. Treatment of
cells with 0.023–16 nM TPA and 0.030–20
ng/mL (5.0 pM–3.3 nM) EGF produced a
dose-dependent increase of ERK activity
(Figure 1A, C). Parallel measurements of SRE
activation by TPA or EGF are shown in
Figure 1B and D. To facilitate the compari-
son, the optical densities of phospho-ERK
shown in Figure 1A and C are plotted with
the SRE reporter activation shown in Figure
1B and D. TPA treatment yielded similar
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vation, suggesting that SRE activation is a
legitimate, alternative indicator of ERK activa-
tion under deﬁned conditions. We observed a
significant increase of SRE activation at the
EGF concentration needed to produce
detectable activation of ERK-2. The dose–
response curve of ERK activation by EGF did
not completely coincide with the one of SRE-
Luciferase activation (Figure 1D). This sug-
gests that other MAP kinases such as Jun
N-terminal kinase and/or p38 kinase might
be involved in the activation of SRE at pro-
gressively higher concentrations of EGF (26).
Two SRE reporter clones (S12 and S13)
showed different basal luciferase activity and
produced 3.3- and 2.9-fold increase of
luciferase activity by 5.3 nM TPA, respec-
tively (data not shown). When the data are
plotted as percent of maximum activation,
the two clones show similar dose response to
TPA or EGF treatment (Figure 2A, B).
Concentrations > 0.2 nM TPA or > 0.12
ng/mL (0.02 nM) EGF produced a signifi-
cant increase in SRE activation. 
Activation of AP-1-dependent gene expres-
sion and transformation response by TPA or
EGF. Two independent AP-1 reporter clones
(A3 and A9) also showed concentration-
dependent activation of AP-1-dependent
transcription in response to TPA or EGF
treatment (Figure 3A, B). Apparent threshold
concentrations for producing signiﬁcant acti-
vation of AP-1 are 0.2 nM TPA and 0.12
ng/mL (19.8 pM) EGF. We determined
anchorage-independent transformation
response to TPA or EGF at varying concen-
trations. More than 0.2 nM TPA or 0.12
ng/mL (0.02 nM) EGF—concentrations that
produced signiﬁcant activation of SRE or AP-
1—also produced a significant increase in
transformation response (Figure 4A, B). 
Activation of NFκB-dependent gene
expression and transformation response by
TNF. NFκB reporter clones N3 and N5
showed concentration-dependent NFκB
activation by TNFα (Figure 5). Significant
NFκB activation occurred at 0.4 U/mL, and
maximal activation occurred at 33 U/mL.
Determination of the transformation
response to TNFα revealed that although the
number of colonies increased up to 11 U/mL
TNFα, it sharply decreased with higher doses
(Figure 6A). This dose–response curve is con-
sistent with our previous report (5). The
number of total objects (colonies plus single
cells) at the time of soft agar assay decreased
at more than 11 U/mL TNFα (Figure 6B,
lower panel). This suggests that the decreased
transformation response at high dose is
caused by TNFα induced cell toxicity
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Figure 1. Dose-dependent correlation of TPA- and EGF-mediated ERK and SRE activation. (A,C) Activation of ERK by TPA or EGF, respectively. Phosphorylated
ERK-1/2 (p-ERK-1/2) is used as an index of ERK activation, while total ERK level (ERK-1/2) serves as loading control. (B,D) The correlation between ERK and SRE
activation by TPA or EGF, respectively. Relative intensity of the phosphorylated ERK-2 band was plotted as percent activation (ERK-2). The mean value of three
independent experiments was plotted. SRE activation (SRE-Luc) was measured as described in “Materials and Methods.” Error bars inticate SD. Data are pre-
sented as percent of maximal activation. Solvent control (no tumor promoter) values were subtracted before plotting. 
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Figure 2. Signiﬁcant SRE activation requires at least 0.2 nM TPA or 0.12 ng/mL EGF. Two independent SRE-
luciferase reporter cells (S13 and S12) were treated with varied concentrations of (A) TPA or (B) EGF.
Error bars indicate SD.
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)(27,28). A comparison of TNFα-induced
NFκB activation and transformation response
for clone N3 is shown in Figure 6B (top
panel). The most noteworthy feature of this
comparison is the dissociation of TNFα-
mediated NFκB activation from the transfor-
mation response at progressively higher doses.
The slight shift in the TNFα dose response
for transformation of N3 clonal cells, relative
to the parental clone 41 cell line, indicates
that we selected clones with greater sensitivity
to the cytotoxicity response. 
We chose to focus on the correlation
between second messenger activation and
inducible (≥ 2-fold) transcriptional activities.
Less than a 2-fold induction does not provide
sufﬁcient separation from background signal
standard deviation to provide meaningful
comparisons. Because TPA or EGF produced
< 2-fold maximal induction of NFκB
activation, and because TNFα produced less
than 2-fold maximal AP-1 activation,
dose–response analyses for the respective lig-
and-induced transcriptional activities were
not pursued using the respective cloned
reporter cell lines.
Discussion
These results establish that there are thresholds
of activation of ERK-1, ERK-2, AP-1, or
NFκB above which there is risk of transforma-
tion by TPA, EGF, or TNFα. Concentrations
> 0.2 nM (0.12 ng/mL) TPA (Figure 4A),
0.12 ng/mL (0.02 nM) EGF (Figure 4B), or
1 U/mL TNFα (Figure 6A) produced signiﬁ-
cant increases in transformation response by
mouse epidermal JB6 cells, while responses to
lower concentrations were comparable to
background. Fifty percent of maximal
response to TPA was seen at 0.69 ± 0.19 nM
for SRE activation, AP-1 activation, and
transformation response (Figure 7). Fifty per-
cent of maximal response to EGF was seen at
1.4 ± 0.6 ng/mL (229 pM) for SRE activa-
tion, AP-1 activation, and transformation
response (Figure 8). A concentration of 10
ng/mL TPA and 10 ng/mL EGF are equal to
1.6 nM and 0.17 nM, respectively. These rel-
atively high concentrations, which produce
maximal response, are typical concentrations
used in previous reports (11,29). The magni-
tude of AP-1 activation thus predicts transfor-
mation response by TPA or EGF. Because
AP-1 activation is required for TPA- or EGF-
induced transformation of JB6 cells (13) and
for tumor promotion in mouse skin (7), AP-1
activation is a good predictor of transforma-
tion response by TPA or EGF. This finding
allows one to do 3-hr assays instead of time-
consuming 14-day assays to assess promotion
of transformation response to TPA or EGF.
Regression analysis shows the close rela-
tionship between SRE activation, AP-1 acti-
vation, and transformation responses to TPA
or EGF. The magnitude of AP-1 activation
by TPA or EGF shows a linear relationship to
the magnitude of SRE activation with a slope
close to 45° (Figure 9A). Moreover, the mag-
nitude of transformation response is linearly
related to the magnitude of AP-1 activation
by TPA or EGF, again with a slope close to
45 degrees (Figure 9B). This indicates that
the magnitude of either SRE activation or
AP-1 activation constitutes a reliable predic-
tor of the magnitude of transformation risk in
response to TPA or EGF. The amount of
SRE activation indicates the amount of ERK
activation by TPA or EGF (Figure 1B).
Consistent with previous findings (11,12),
ERK activation not only is essential but is
also a major determinant of AP-1 activation,
which in turn is a major determinant of
transformation response to TPA. 
SRE activation leading to c-fos transcrip-
tion, although a good risk indicator, is not
sufﬁcient for transformation because promo-
tion-resistant cells can induce c-fos expression
in response to TPA or EGF (24). Thus, the
tight correlation between ERK and SRE
activity in the initial 3 hr with the transfor-
mation response suggests that these acute
molecular readouts are also good alternative
indicators of subsequent transformation
response to TPA and EGF. 
EGF and TNFα are biologically more
significant tumor promoters than TPA
because these are endogenous growth fac-
tors/cytokines produced in response to many
stimuli. In vivo studies with TNFα knockout
mice showed TNFα is required for TPA-
induced tumor promotion (30,31). The pre-
sent study indicates that TNFα has a
concentration range for producing transfor-
mation response. At TNFα concentrations
associated with maximal transformation
response (11 U/mL), NFκB activation is
approximately 70% of maximum. Moreover,
NFκB activation continues to increase at pro-
gressively higher TNFα concentrations,
despite the sharp switch from transforming
activity to cytotoxicity. This dissociation
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Figure 3. AP-1 activation requires at least 0.2 nM TPA or 0.12 ng/mL EGF. Two independent AP-1-luciferase
reporter cells (A3 and A9) were treated with varying concentrations of (A) TPA or (B) EGF. Error bars indicate
SD.
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Figure 4. Significant transformation response requires at least 0.2 nM TPA or 0.12 ng/mL EGF.
Transformation response of A3 cells by (A) TPA or (B) EGF is shown as number of colonies per 10,000 cells
in soft agar. Two dishes were made for each condition in each experiment. Average number of three inde-
pendent experiments was used. Error bars indicate SD.
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Figure 5. NFκB activation requires >0.4 U/mL TNFα.
Two independent NFκB-luciferase reporter cells
(N3 and N5) were treated with varied doses of
TNFα. Error bars indicate SD.
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)suggests that, although activation of NFκB
plays a role in producing risk, other factors
must also be important in determining risk of
TNFα-induced transformation. Low levels
spanning the concentration range that pre-
cedes the cytotoxic response are predictive for
transformation risk due to TNFα exposure,
whereas high levels of NFκB activation asso-
ciated with cytotoxicity have no predictive
value. 
In practical situations, multiple tumor
promoters might be applied sequentially or
simultaneously. Assaying an unknown agent
in parallel with tumor promoter TPA, EGF,
or TNFα at their threshold concentrations
for promotion of transformation will allow
one to determine whether exposure to the
unknown agent alone activates transcription
factor at levels that exceed transformation-rel-
evant thresholds. The unknown agent can
also be used in combination with one of the
known tumor promoters, and the incremen-
tal activation due to the unknown can be
compared with transformation-relevant levels
of activation. Because the JB6 model has
proved to be predictive for revealing molecu-
lar events that drive or prevent tumor promo-
tion or maintain tumor phenotype in vivo (7)
or in a human keratinocyte model (8,9), this
model can be used as a sensitive and rapid
initial screen to identify agents likely to pre-
sent risk of tumor promotion.
The 3-hr transcription factor activation
assays are reliable predictors of 14-day trans-
formation outcomes in the JB6 model and of
mouse skin tumor promotion. Activation of
AP-1 and NFκB at 3 and 18 hr is required
for transformation in the JB6 model (13,15).
This is true for multiple classes of agents (6,
32–39). An agent that does not activate AP-1
or NFκB is unlikely to act as a tumor pro-
moter. Although activation of AP-1 or NFκB
is not sufﬁcient for promotion of transforma-
tion, stimulated activation of either transcrip-
tion factor increases the risk of tumor
promotion. It is also known that the elevated
AP-1 activation seen at 6 hr is sustained in
mouse epidermis after 2 weeks of twice-
weekly tumor promotion, and that, when
dominant negative jun expression inhibits
tumor promotion, it also inhibits the 2-week
induction as well as the 6-hr induction of
AP-1 (7).
Previous studies revealed that magnetic
field exposure does not affect TPA-induced
transformation response of JB6 cells (40,41).
Defining molecular events that are required
for cell transformation and thresholds in sig-
naling pathways associated with the transfor-
mation response will allow for flexibility in
the application of in vitro model systems
directed at defining relative cancer risks at
low-dose exposures. Molecular responses in
cells cotreated with known tumor promoters
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Figure 6. Low-dose similarity of TNFα-dependent dose–response curves for transformation response and
NFκB activation. (A) Transformation response of Cl 41 and N3 cells to TNFα. Colonies > 8 cells were
scored. Results represent the combined average of three independent experiments using duplicate sam-
ples (n = 6). Error bars indicate SD. (B) A comparison of TNFα-mediated NFκB activation (NFκB-Luc) and
transformation response (Tx) for N3 cells (top panel). Percent transformation response = sample/maximum
number of colonies × 100. The number of total objects (colonies plus single cells) per dish is plotted in the
lower panel.
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Figure 7. Similar thresholds for TPA-mediated SRE
activation, AP-1 activation, and transformation.
TPA-mediated SRE activation of S13 cells (SRE-
Luc) from Figure 2A, AP-1 activation of A3 cells
(AP-1-Luc) from Figure 3A, and transformation
response (Tx) of A3 cells from Figure 4A were plot-
ted as percent maximum activation for direct com-
parison. Percent transformation response =
(sample – number of colonies in control dish)/(max-
imum number of colonies – number of colonies in
control dish) × 100. Error bars indicate SD.
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Figure 8. EGF-mediated transformation threshold is
similar to AP-1 activation threshold. EGF-mediated
SRE activation (SRE-Luc) of S12 cells from Figure
2B, AP-1 activation (AP-1-Luc) of A3 cells from
Figure 3B, and transformation response (Tx) of A3
cells from Figure 4B were plotted as percent maxi-
mum activation to facilitate the direct comparison.
Percent transformation response = (sample num-
ber of colonies in control dish)/(maximum number
of colonies – number of colonies in control dish) ×
100. Error bars indicate SD.
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Figure 9. AP-1 response is predictive for risk of transformation by TPA or EGF at both low and high doses.
(A) Linear regression of AP-1 activation and SRE activation by TPA (R2 = 0.96 and 0.94 for TPA and EGF,
respectively). (B) Linear regression of transformation response and AP-1 activation by TPA and EGF(R2 =
0.94 and 0.81 for TPA and EGF, respectively).and unknown environmental contaminants
(physical or chemical) can rapidly be quanti-
tated to determine whether transformation-
related signal transduction is induced by the
unknown contaminant over a rationally
selected range of TPA, EGF, or TNFα con-
centrations. Because the molecular response
to TPA, EGF, and TNFα can be directly cor-
related with transformation response in the
agar assay, the results can provide rapid analy-
sis of relative risks. Within this context, we
are particularly interested in the cancer risk
associated with low-dose radiation exposures.
It is difficult to unambiguously define the
biological consequences of low-dose radiation
exposures due primarily to low signal-to-noise
ratio. We are optimistic that a cotreatment
strategy using low-dose radiation and known
tumor promoters will allow a robust measure
of the effects of radiation on transformation-
related signal transduction. If successful, this
work will have broader applications in envi-
ronmental health concerns, concerns that
invariably involve low-dose exposures.
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